Letaxaban

Letaxaban (TAK-442) is an orally active and selective direct FXa inhibitor. Letaxaban is a drug with dual anticoagulant and anti-inflammatory activity that works by directly inhibiting FXa and by intervening in the PAR1 signaling pathway. Letaxaban can be used in the study of thrombotic diseases, cardiovascular diseases and inflammation-related diseases[1].

Product Specifications

CAS Number

[870262-90-1]

Product Name Alternative

TAK-442

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Factor Xa

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/letaxaban.html

Smiles

ClC1=CC2=C(C=C1)C=C(C=C2)S(C[C@@H](O)C(N3CCC(N4C(NCCC4)=O)CC3)=O)(=O)=O

Molecular Formula

C22H26ClN3O5S

Molecular Weight

479.98

Precautions

P261-P280-P302+P352

References & Citations

[1]Shinozawa E, et al. TAK-442, a direct factor Xa inhibitor, inhibits monocyte chemoattractant protein 1 production in endothelial cells via involvement of protease-activated receptor 1[J]. Frontiers in Pharmacology, 2018, 9: 1431.